empagliflozin – Medxy AI

Anaemia as a Predictor of Iron Dysregulation and Modulator of Empagliflozin Response in Heart Failure with Reduced Ejection Fraction: Insights from the EMPATROPISM-FE Trial

By MedXY 08/13/2025

In patients with heart failure and reduced ejection fraction, anaemia predicts iron homeostasis disruption and influences response to empagliflozin, which increases myocardial iron and improves cardiac function and exercise capacity.

Cardiology Clinical Updates news Specialties

Empagliflozin’s Impact on Peripheral Microvascular Function in HFpEF: A Novel Vascular Insight

By MedXY 08/13/2025

Empagliflozin alters peripheral microvascular responses in HFpEF patients, enhancing insulin-mediated vasodilation but reducing acetylcholine responsiveness, suggesting a targeted vascular mechanism distinct from general endothelial or smooth muscle effects.

Diabetes & Endocrinology Nephrology news Specialties

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial

By MedXY 08/13/2025

The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.

Clinical Updates Diabetes & Endocrinology Nephrology news Specialties

Dual Renal Protection: Finerenone Plus Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

By MedXY 08/09/2025

Combining finerenone with empagliflozin provides superior reduction in albuminuria for patients with chronic kidney disease and type 2 diabetes, without increased adverse events.